Interaction reference

GLP-1 receptor agonists with Insulin

Combining a GLP-1 receptor agonist with insulin meaningfully increases hypoglycemia risk. The combination is common and safe with proactive dose adjustment.

Hypoglycemia risk — your insulin dose typically needs to come down 10-20% when starting any GLP-1.

Also known as: Lantus, Levemir, Humalog, NovoLog, Tresiba, Toujeo

Per-GLP-1 breakdown

Wegovysemaglutide 2.4 mg
Major
Mechanism: Both lower blood glucose. GLP-1s also enhance endogenous insulin secretion in a glucose-dependent way, so the additive effect is real but predictable.
What to do: Reduce basal insulin dose by 10-20% at GLP-1 initiation and at each dose escalation. Watch fasting glucose for the first 2-4 weeks. Bolus insulin may also need downward titration once GLP-1s reach maintenance dose.
Zepboundtirzepatide
Major
Mechanism: Both lower blood glucose. GLP-1s also enhance endogenous insulin secretion in a glucose-dependent way, so the additive effect is real but predictable.
What to do: Reduce basal insulin dose by 10-20% at GLP-1 initiation and at each dose escalation. Watch fasting glucose for the first 2-4 weeks. Bolus insulin may also need downward titration once GLP-1s reach maintenance dose.
Ozempicsemaglutide
Major
Mechanism: Both lower blood glucose. GLP-1s also enhance endogenous insulin secretion in a glucose-dependent way, so the additive effect is real but predictable.
What to do: Reduce basal insulin dose by 10-20% at GLP-1 initiation and at each dose escalation. Watch fasting glucose for the first 2-4 weeks. Bolus insulin may also need downward titration once GLP-1s reach maintenance dose.
Mounjarotirzepatide
Major
Mechanism: Both lower blood glucose. GLP-1s also enhance endogenous insulin secretion in a glucose-dependent way, so the additive effect is real but predictable.
What to do: Reduce basal insulin dose by 10-20% at GLP-1 initiation and at each dose escalation. Watch fasting glucose for the first 2-4 weeks. Bolus insulin may also need downward titration once GLP-1s reach maintenance dose.
Foundayoorforglipron
Major
Mechanism: Both lower blood glucose. GLP-1s also enhance endogenous insulin secretion in a glucose-dependent way, so the additive effect is real but predictable.
What to do: Reduce basal insulin dose by 10-20% at GLP-1 initiation and at each dose escalation. Watch fasting glucose for the first 2-4 weeks. Bolus insulin may also need downward titration once GLP-1s reach maintenance dose.

Sources

Wegovy prescribing information — drug interactions — FDA accessdata
GLP-1 receptor agonists in combination with insulin — Diabetes Care

See other interactions

Full interaction index